FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the ... cancer and these are usually associated with old age and environmental factors such as smoking.” ...

Grants of Intellectual Property in 2024 Endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States.

Commenced enrollment and dosing in DURIPANC Phase 1b/2 study combining Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi ... of reproductive age, or approximately ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Commenced enrollment and dosing in DURIPANC Phase 1b/2 study combining Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of late-stage ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the ... cancer and these are usually associated with old age and environmental factors such as smoking.” ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the ... cancer and these are usually associated with old age and environmental factors such as smoking." ...

He said that the rumours had likely originated from AZ’s succession planning as several board members had retired because of age limits set ... of Tagrisso and Imfinzi, adding that in the ...

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), ...

AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...